디티앤씨알오

383930KOSDAQ

46.5 / 100

Reference Date: 2026-10-23

Financial Score19.0 / 40

News Sentiment12.5 / 25

Momentum15.0 / 20

Disclosure0.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 32.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

DT&CR is a Full-Service CRO providing non-clinical and clinical trial services across pharmaceuticals, medical devices, and health functional foods, offering integrated solutions from early-stage drug development to FDA approval. In 2025, revenue increased by 32.7% year-over-year to 47.7 billion won, driven by specialized services such as the expanded PK/PD center, which scientifically analyzes drug candidate characteristics.

Number of Employees

314people

Average Salary

47.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.19Industry Average 1.204.0Point

In line with industry avg

ROE

-10.33Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

54.18Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲34.0% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲28.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -19.9% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (38%)

Current 2,330Won52-week high 3,74552-week low 1,450

1-month return6.0Point

1m +32.46% (strong rise)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

9 totalPositive 0Neutral 2Negative 7

Negative[기재정정]소송등의판결ㆍ결정(일정금액이상의청구)2026-10-07
Negative[첨부정정]소송등의판결ㆍ결정(일정금액이상의청구)2026-09-30
Negative소송등의판결ㆍ결정(일정금액이상의청구)2026-09-30
Negative소송등의판결ㆍ결정(일정금액이상의청구)2026-09-30
Neutral[기재정정]신주인수권행사가액의조정2026-09-29